Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CCKBR | P32239 | 1/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 10/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.44 |
| ▸ | HRH2 | P25021 | 2/20 | 0.41 |
| ▸ | HRH1 | P35367 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8234436 | 0.90 | CACNA1B (0.56) | MAPK1CACNA1BNR1I2CYP3A4 | |
| SCHEMBL13932880 | 0.88 | MAPK1 (0.53) | KMT2AMEN1MAPK1ALDH1A1LMNA | |
| SCHEMBL4278741 | 0.86 | CCKBR (0.45) | KMT2AMEN1CCKBRCACNA1BNR1I2 | |
| SCHEMBL4284293 | 0.86 | CCKBR (0.45) | KMT2AMEN1CCKBRCACNA1BNR1I2 | |
| SCHEMBL4280044 | 0.84 | CACNA1B (0.53) | KMT2ACACNA1BNR1I2CYP3A4 | |
| SCHEMBL13932876 | 0.83 | MAPK1 (0.53) | KMT2AMEN1MAPK1ALDH1A1LMNA | |
| SCHEMBL13932891 | 0.83 | ALDH1A1 (0.47) | KMT2AMEN1MAPK1ALDH1A1LMNA | |
| SCHEMBL13932875 | 0.81 | MMP1 (0.49) | KMT2AMEN1MAPK1ALDH1A1LMNA | |
| SCHEMBL4278449 | 0.80 | CACNA1B (0.53) | CACNA1BNR1I2CYP3A4 | |
| SCHEMBL13932883 | 0.80 | MAPK1 (0.48) | KMT2AMEN1MAPK1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-01 | — | — | US | disclosed |
| US-20120172429-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI- INFLAMMATORY AGENTS | THE GENERAL HOSPITAL CORPORATION | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172429-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI- INFLAMMATORY AGENTS | TRPV1, CACNA1B, ORAI1 | KMT2A 2190/4885MEN1 2018/4885MAPK1 2064/4885 |
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | OPRL1, MRGPRX1, RAMP1 | KMT2A 4362/4885MEN1 1225/4885MAPK1 2132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.